bluuebunny/crossref_metadata_2025 huggingface dataset:
603 Endothelial dysfunction is associated with hypertensive disorder during pregnancy
Authors: Avallone Carlo Maria , Nuzzo Martina , Rota Irene , Persico Nicola , Carugo Stefano , Bollati Valentina , Vicenzi Marco
Published: December 2021

Aims

Arterial hypertension (AH) is one of the main determinants of clinical disorders during pregnancy affecting 2% to 10% of pregnancies with a substantial public health impact. Both endothelial injury and increased vascular reactivity have been reported to be involved in the pathogenesis of pre-eclampsia syndrome. Abnormal patterns in brachial artery Doppler velocities have been shown to be predictive of pre-eclampsia in first trimester. The aim of this study is to investigate whether flow-mediated dilation (FMD) and Doppler flow derived-parameters can predict the occurrence of AH.

Methods and results

The study population consisted of pregnant women (mean age 32 years) who had been referred to the IRCCS Fondazione Ca’ Granda Policlinico of Milan. None of them had any medical issues and was taking any medications at the time of pregnancy. FMD was performed on left brachial artery according to expert recommendation. Measurements of brachial artery diameter and flow have been collected at rest, shortly before cuff release and then 5-, 15-, 30-, 60-, and 90-s during hyperaemia phase. Among Doppler measurements, systolic and diastolic velocity (Vs and Vd, respectively) as well as mean velocity (mean V) were considered. In addition, the pulsatility index (PI) and resistance index (RI) were calculated. A 3-months follow-up was planned in order to detect the presence of AH. All data were expressed as the median. U-test (Mann–Whitney analysis) was performed to test difference among hypertensives and non-hypertensives We recruited 48 women (median age 32 yeas) whose 4 (8.5%) developed AH during pregnancy. These latter had statistically significant higher systolic velocity measured at 5 s after the release of distal occlusion (126 cm/s vs. 173 cm/s; P < 0.05). No other velocity Doppler data [diastolic velocity (Vd), mean velocity (mean V), PI, RI, TAMAX, and TAMEAN] showed a statistical significant association with AH development.

Conclusions

The present study suggests that the vascular assessment through Doppler during FMD procedure may foresee the development of hypertensive disorder in pregnancy. Our result provides the first evidence that the peak systolic velocity of brachial artery may represent a marker of early endothelial activation or damage, that can be directly involved in the pathophysiological mechanisms of the hypertensive disorders in pregnancy.
158 Racial differences in val122Ile associated transthyretin cardiac amyloidosis
Authors: Argirò Alessia , Zampieri Mattia , Batra Jaya , Rosenblum Hannah , Burkhoff Daniel , Maurer Mathew , Olivotto Iacopo , Cappelli Francesco
Published: December 2021

Aims

The valine-to-isoleucine substitution (Val122Ile) is the most common variant of transthyretin (TTR) amyloidosis in the USA, primarily affecting individuals of African descent and leading to a restrictive cardiomyopathy. This variant has recently been identified in a cluster of White individuals in Italy. In this study we aimed to investigate differences in the clinical phenotype of Val122Ile associated TTR cardiac amyloidosis (ATTR-CA) between Black and White individuals.

Methods and results

In this retrospective study of 70 patients (mean age 72 years) with Val122Ile associated TTR ATTR-CA, cardiac chamber performance was compared using noninvasive pressure-volume analysis. Compared to White patients (n = 17), Black individuals (n = 53) had lower systolic blood pressures (110 vs. 131 mmHg, P < 0.001), reduced pulse pressures (41 vs. 58 mmHg, P < 0.001), and impaired renal function (eGFR 46 vs. 67 mL/min/1.73 m2, P < 0.001) at presentation. Systolic properties and arterial elastance were similar. Black patients had an end-diastolic pressure-volume relationship shifted upward and leftward relative to White patients, indicating reduced left ventricular chamber capacitance. Pressure-volume area at a left ventricular end-diastolic pressure of 30 mmHg was lower in Black compared to White individuals (8055 mmHg*ml vs. 11 538 mmHg*ml, P = 0.008).

Conclusions

Despite presenting at a similar age to White patients, Black individuals with Val122Ile associated ATTR-CA have a greater degree of cardiac chamber dysfunction at the time of diagnosis due to impaired ventricular capacitance. Whether these differences are attributable to amyloidosis or other cardiovascular disease requires further study.
587 Exercise induced pulmonary hypertension in hypertrophic cardiomyopathy: a combined cardiopulmonary exercise test-echocardiographic study
Authors: Re Federica , Halasz Geza , Moroni Francesco , Beltrami Matteo , Baratta Pasquale , Avella Andrea , Zachara Elisabetta , Olivotto Iacopo
Published: December 2021

Aims

Pulmonary arterial hypertension (PAH) has been described in patients with hypertrophic cardiomyopathy (HCM) and it was associated with a worse prognosis. Nevertheless in most HCM patients, despite normal pulmonary pressures at rest, congestive symptoms are elicited by exercise. In the present study, combining cardiopulmonary exercise test (CPET) with echocardiography, we aimed to evaluate the presence of exercise-induced pulmonary hypertension (EiPAH) its role in functional limitation and its prognostic significance in a cohort of patients with obstructive and non-obstructive HCM.

Methods and results

182 HCM patients (35% females, mean age 47.5 ± 15.9) undergoing CPET. During CPET, LVOT velocities and trans-tricuspid gradient were measured. Thirty-seven patients (20%) developed sPAP > 40 mmHg at peak exercise (EiPAH). EiPAH was associated with an lower exercise performance, larger left atrial volumes, higher left ventricular gradient and higher VE/VCO2 slope .At multivariable model baseline sPAP (P < 0.0001) and baseline left ventricular obstruction (LVOT) (P = 0.028) were significantly associated with EiPAH .Kaplan-Meier curve analysis showed EiPAH was a significant predictor of HCM –related morbidity (hazards ratio: 6.21, 95% CI: 1.47–26.19; P = 0.05; 4.21, 95% CI: 1.94–9.12; P < 0.001) for the primary and the secondary endpoint respectively.

Conclusions

EiPAH was present in about one fifth of HCM patients without evidence of elevated pulmonary pressures at rest, and was associated with adverse clinical outcome. Diagnosing EiPAH by exercise echo/CPET may help physicians to detect early stage of PAH requiring a closer clinical monitoring and individualized treatment strategies.
641 Left ventricular non-compaction as a distinct cardiomyopathy or a phenotypic feature: a case report
Authors: De Zan Giulia , Marconetto Camilla , Carli Alessandro , Parodi Alessandro , De Vecchi Simona , Patti Giuseppe
Published: December 2021

A 71-year-old male with no cardiovascular risk factors and a history of two uninvestigated episodes of loss of consciousness one year before, presented in our department to undergo a treadmill exercise stress test in relation to inverted T waves in V5-V6 on his basal ECG and frequent ventricular extrasystoles (PVCs). The stress test was positive for inducible ischemia, with a significant depression of the ST-segment in the lateral lead. A transthoracic echocardiography revealed normal thicknesses and volumes of the left ventricle (LV) with a dyskinesia of the lateral wall and a mildly reduced ejection fraction (EF) up to 46%. Epicardial surface was unremarkable. Next, a coronary angiography showed no critical obstruction in the epicardial coronary arteries. In order to further investigate the frequent PVCs and the reduction of the LV systolic function, a cardiac magnetic resonance (CMR) with paramagnetic contrast agent was performed. The images outlined the presence of non-compaction in the distal lateral wall and apex with a late gadolinium enhancement (LGE) in the epicardial portion of the lateral wall (Figure 1). Moreover, the CMR showed an adipose infiltration of the interventricular septum and thickened right ventricular trabeculae, suggesting an overlap with arrhythmogenic left ventricular dysplasia. During the subsequent follow-up, the patient was implanted with an implantable cardiac defibrillator (ICD), after two reported episodes of loss of consciousness and an electrophysiology study (EPS) resulting in the induction of a symptomatic ventricular tachycardia. Non-compaction cardiomyopathy is a rare and still relatively novel nosological entity, which can sometimes be observed in the same patient with other forms of cardiomyopathy. In the context of an unexplained reduction of LVEF and frequent PVCs, the accuracy of CMR in describing cardiac morphology and myocardial layer remains an indispensable tool to detect otherwise underdiagnosed potentially fatal cardiomyopathies.
406 A 50 years old man with a late presentation of arrhythmogenic cardiomyopathy
Authors: Dellino Carlo Maria , Bariani Riccardo , Cipriani Alberto , Marra Martina Perazzolo , Pilichou Kalliopi , Iliceto Sabino , Corrado Domenico , Basso Cristina , Rigato Ilaria , Bauce Barbara
Published: December 2021

In January 2014 a 50 years old man without previous medical history experienced a syncopal episode. During evaluation at Emergency department (ED) a sustained ventricular tachycardia (VT) with haemodynamic compromise was found and successfully treated with DC shock. The patient was admitted to the Coronary Care Unit (CCU) where the ECG showed diffuse low QRS voltages and flattened T waves. Coronary angiography showed normal coronary arteries. 2-D echocardiogram documented the presence of a mildly dilated left ventricle (LV) with a mildly decreased systolic function (EF : 41%); the right ventricle (RV) was severely dilated (REDV : 41 cmq/mq) with a severe systolic dysfunction (fractional area change: 21%) with diffuse hypokinesia and akinesia of subtricuspid region. Cardiac magnetic resonance (CMR) confirmed ventricular dimensional and kinetic abnormalities and tissue characterization sequences demonstrated the presence of fatty infiltration of the epicardial segments of LV lateral wall and of RV free wall. After gadolinium injection, late gadolinium enhancement (LGE) presented the same distribution of the fatty infiltration. A diagnosis of arrhythmogenic cardiomyopathy (AC) was made and ICD in secondary prevention was implanted. The patient was treated with Sotalol (240 mg/daily) and remained asymptomatic and free from sustained ventricular arrhythmias for five years. In January 2019 he started to complain asthenia, dyspnoea (NYHA II) and anorexia and he was admitted to ED where a persistent slow VT was detected. Echocardiogram showed a severely dilated LV with severe systolic dysfunction (EF: 30%) with substantially unchanged RV features. One year later he experienced an heart failure (HF) episode with further reduction of LV systolic function (EF: 21%). Cardiopulmonary test documented a severe ventilation/perfusion mismatch (VE/VCO2 slope 50.6) and severe reduction of the exercise tolerance (VO2 peak 9.2 ml/kg/min). In March 2021 the patient started heart transplantation check list. Three weeks after the discharge he was transplanted. In conclusion, this clinical case highlights an infrequent late presentation of AC, with an initial high arrhythmic burden and a following rapid progression to refractory HF requiring heart transplantation.
188 Disarming the bomb in AL amyloidosis: a case report
Authors: Licchelli Luca , De Michieli Laura , Sinigiani Giulio , Da Pozzo Stefano , Barbera Mila Della , Rizzo Stefania , Cecchin Diego , Berno Tamara , Cipriani Alberto
Published: December 2021

Aims

Light-chain amyloidosis (AL) is a rapidly progressive systemic disease commonly involving also the myocardium, with poor outcome if lately diagnosed and treated. Clinical presentation can be widely varied, ranging from unapparent disease with soft symptoms to acute heart failure syndromes, requiring urgent therapies and supports.

Methods and results

A 52-year-old women came to our outpatient cardiomyopathy clinic because of hypertrophic cardiomyopathy (HCM) suspicion. Family history included a paternal cousin with diagnosis of unspecified cardiomyopathy and cardiac arrest. Her medical history was unremarkable until few months ago, when she started to complain with palpitations and asthenia. Given that both electrocardiogram and echocardiogram had previously showed signs of left ventricular (LV) hypertrophy, she was referred to us for HCM evaluation. Our physical examination was unremarkable, in particular there were no signs of central or peripheral venous congestion. Electrocardiogram showed a diffuse strain pattern with inferolateral ST-depression and T-wave inversion. Echocardiogram showed a thicked interventricular septum (17 mm), a pseudo-normal transmitral filling pattern with mild increase of LV filling pressure (E/E′ 11), a severely dilated left atrium (51 ml/mq). To complete the diagnostic path for HCM, we asked for a cardiac magnetic resonance (CMR), which two months later gave to us the diagnosis of myocardial amyloid infiltration. The diagnosis was quite surprising, because the patient was fine, 6 min walking test assessed a good functional capacity (500 m), no heart failure signs were recorded. So, we sent the patient to perform bone scintigraphy, which showed Perugini 0 uptake, and blood exam, showing, instead, rise of lambda free light chains, cardiac troponin (41.5 ng/l) and NTproBNP (5318 ng/l). Patient was urgently referred to haematologists, who using bone marrow and fat pad biopsy diagnosed a multiple myeloma with stage IV sec. Mayo AL amyloidosis. (Cy)BorD therapy was started, reaching a complete response in 4 months.

Conclusions

Diagnosis of AL amyloidosis is tricky due to heterogeneous clinical onset and multi-organ involvement. Cardiologist community should be aware of this condition, phenotypically mimicking HCM, but with very different management, in order to favour early diagnosis, prompt referral and treatment initiation. This case teaches that only 1. clinical awareness and 2. multidisciplinary approach can lead to disarm the bomb in AL amyloidosis.
180 Cognitive disorders in takotsubo syndrome: incidence, short, and long term outcome. Results from a prospective multi-centre registry
Authors: Mallardi Adriana , Santoro Francesco , Leopizzi Alessandra , Vitale Enrica , Iacoviello Massimo , Brunetti Natale Daniele
Published: December 2021

Aims

Takotsubo syndrome (TTS) is an acute and reversible left ventricular dysfunction, whose pathophysiological mechanisms are not completely known. There are evidence suggesting a possible link between neurological disease and TTS. Aim of the study was to evaluate incidence and prognostic value of cognitive neurological disorders among TTS patients.

Methods and results

379 consecutive patients were enrolled in a prospective multicentre registry. History, clinical features, echocardiographic parameters, in-hospital complications and long-term Follow-up events of all patients were recorded. Cognitive neurological disorders included Alzheimer disease, old age dementia and cognitive impairment for other causes. Prevalence of cognitive neurological disorders among TTS patients was 5.5% (num = 21). Among this subset of patients 48% (num = 10) had Alzheimer syndrome, 24% (num = 5) old age dementia and 28% (num = 6) cognitive impairment for other causes. Compared to the control group, these patients were older (81 ± 5 vs. 71 ± 12, P = 0.01) and predominantly men (24% vs. 9%, P = 0.01). No differences in term of cardiovascular risk factors and left ventricular ejection fraction at admission and discharge were found among the two groups. TTS patients with cognitive neurological disorders experienced higher rate of in-hospital complications (62% vs. 28%, P = 0.01), that were mainly driven by higher rate of pulmonary oedema (14% vs. 9%, P = 0.01), cardiogenic shock (29% vs. 8%, P = 0.01), death (24% vs. 4% P = 0.01), ischaemic stroke (10% vs. 4%, P = 0.01), and left ventricular thrombi (10% vs. 3%, P = 0.01). At long-term follow-up patients with cognitive neurological disorders when compared to those without, experienced higher rate of mayor cardiovascular events (48% vs. 16%, P = 0.01), cardiovascular re-hospitalization (14% vs. 10%, P = 0.01) and death (43% vs. 9%, P = 0.01).

Conclusions

TTS patients with cognitive neurological disorders had an increased risk of in and out of hospital mayor cardiac adverse events and mortality at short and long-term follow-up.
84 Left atrial reverse remodelling in dilated cardiomyopathy
Authors: Nuzzi Vincenzo , Raafs Anne , Manca Paolo , Henkens Michiel T.h.M. , Gregorio Caterina , Boscutti Andrea , Verdonschot Job , Hazebroek Mark , Knackstedt Christian , Merlo Marco , Stolfo Davide , Sinagra Gianfranco , Heymans Stephane R.B.
Published: December 2021

Aims

Left atrial (LA) dilation is associated a with worse prognosis in several cardiovascular settings but therapies can promote LA reverse remodelling. Characterizing and defining the prognostic implications of LA volume (LAVI) reduction in dilated cardiomyopathy (DCM).

Methods and results

Consecutive DCM patients from two tertiary care centres, with available echocardiography at baseline and at 1 year follow-up, were analysed. LA dilation was defined as LAVI >34 ml/m2, Delta (Δ)LAVI was defined as the 1 year relative LAVI reduction. The outcome was a composite of death/heart transplantation/heart failure hospitalization (D/HTx/HFH). Five hundred sixty patients were included [age 52 ± 13 years; left ventricular ejection fraction (LVEF) 31 ± 10%, LAVI 45 ± 18 ml/m2]. Baseline LAVI had a non-linear association with the risk of D/HTx/HFH, independently from LVEF (P < 0.001). At 1 year follow-up, LAVI decreased in 374 patients (67%, median ΔLAVI 24%, interquartile range 37% 11%). Factors independently associated with ΔLAVI were higher baseline LAVI and lower baseline LVEF. After adjustment for confounders, ΔLAVI showed a linear association with the risk of D/HTx/HHF (HR: 0.92, 95% CI: 0.86 0.99 per 5% decrease, P < 0.001). At 1 year Follow-up, patients with a ≥ 15% reduction in ΔLAVI or LAVI normalization (i.e. Follow-up LAVI ≤34ml/m2) (42% of the cohort) were at lower risk of D/HTx/HFH (HR: 0.49, 95% CI: 0.33 0.74, P < 0.001).

Conclusions

In a large cohort of DCM, 1 year reduction in LAVI is observed in the majority of patients. The association between reduction in LAVI and D/HTx/HHF candidates LA reverse remodelling as complementary early therapeutic goal in DCM.
711 A rare case of takotsubo syndrome induced by pacemaker implantation
Authors: Strangio Antonio , Leo Isabella , Sabatino Jolanda , Romano Letizia Rosa , Bella Sabrina La , Spaccarotella Carmen , Mongiardo Annalisa , Pasceri Eugenia , Aquila Iolanda , Bellomusto Rita , Signorelli Adriano , Santarpia Giuseppe , Curcio Antonio , De Rosa Salvatore , Indolfi Ciro
Published: December 2021

Aims

Takotsubo syndrome (TTS) is an acute cardiac condition characterized by a temporary wall motion abnormality of the left ventricle that mimics an acute coronary syndrome (ACS). TTS usually occurs following emotionally or physically triggering event. We report a rare case of Takotsubo syndrome following a pacemaker implantation.

Methods and results

A 77-year-old woman was admitted to our hospital with a third-degree atrioventricular block. She was asymptomatic with a history of hypertension, diabetes, hyperlipidaemia and extrapyramidal syndrome. Laboratory tests reported High-Sensitive cardiac Troponin T (HS-cTnT) 32.9 ng/L (ULN <14), creatine kinase muscle and brain (CK-MB) 4.1 ng/mL (ULN < 4.94) and NT-proB-type Natriuretic Peptide (NT-proBNP) 1465 pg/ml (ULN < 125). Echocardiography showed a normal left ventricular ejection fraction (EF = 58%) (Figure 2A). The patient underwent dual chamber pacemaker implantation without immediate complications. Three days later, a routine ECG showed new T wave inversions (Figure 1), in absence of symptoms. Echocardiography revealed apical akinesia, with ‘apical ballooning’ (EF 30%) (Figure 2B). Serum cardiac markers were increased (CK-MB 8.2 ng/ml, HS-cTnT 189.7 pg/ml, NT-proBNP 15 005 pg/ml. A coronary angiography excluded obstructive coronary artery disease (Figure 3). Given the impossibility of carrying out a cardiac RMI for the recent pacemaker implantation and after exclusion of other diagnoses, pacemaker implantation induced Takotsubo syndrome was suspected.

Conclusions

The trigger of this case of TTS was the pacemaker implantation, a relatively brief and painless procedure that, in her case could have constitute a considerable emotional and physical stress. To the best of our knowledge 13 cases of TTS after pacemaker implantation have been described to date. Of those cases, four had an asymptomatic course. Therefore, the real incidence of TTS following pacemaker implantation may be underestimated and ECG and echocardiography should always be performed after pacemaker implantation.
131 Cancer and takotsubo syndrome: clinical features, outcome, and inflammatory patterns. Results from a multicentre prospective registry
Authors: Vitale Enrica , Santoro Francesco , Leopizza Alessandra , Mallardi Adriana , Iacoviello Massimo , Brunetti Natale Daniele
Published: December 2021

Aims

Cancer represents one of the major determinants of prognosis in patients with Takotsubo Syndrome (TTS). Aim of this study was therefore to compare clinical features, short- and long-term outcome and inflammatory pattern among TTS patients with history of cancer.

Methods and results

412 consecutive patients with TTS were enrolled in a multicentre prospective registry from July 2007 to February 2021. Clinical features, in and out of hospital MACE, laboratory and imaging data were collected. A sub-analysis evaluating serum interleukins levels among 12 patients with cancer vs. a propensity score matched cohort was performed. Prevalence of history of cancer was 12% (N = 51 pts). Patients with history of cancer were older (77 vs. 72 years, P = 0.01), with a higher percentage of male (23.5% vs. 8.8%, P = 0.01). Diabetes, dyslipidemia, and obesity were more prevalent in patients with cancer (29% vs. 22%, 49% vs. 42%, 25.5% vs. 18.5%, P = 0.01 respectively), while a similar prevalence was found for hypertension and smoke. Left ventricular ejection fraction (LVEF) at admission and discharge was lower in patients with history of cancer (33% vs. 37%, 44% vs. 50%. P = 0.03 respectively). Patients with cancer showed higher incidence of in hospital events (41% vs. 33%, P = 0.01) mainly driven by cardiogenic shock (21.5% vs. 8.5% P = 0.01), in hospital death (13.7% vs. 4.7%, P = 0.01), left ventricular thrombi (9.8% vs. 3.3%, P = 0.01) and ventricular arrhythmias (13.7% vs. 7.4%, P = 0.01). The long-term mortality was higher in patients with history of cancer (31.3% vs. 11.3%, P = 0.01). A distinct inflammatory pattern was found in cancer patients: at admission there were higher levels of IL 2 and VEGF levels (IL-2 3.3 vs. 0.7 pg/ml, P = 0.05, VEGF 476.3 vs. 249.5 pg/ml, P = 0.03); at discharge IL-4 was lower (1.17 pg/ml vs. 2.49 pg/ml, P = 0.04) while VEGF remained higher in subjects with TTS and cancer (406 vs. 128 pg/ml, P = 0.03).

Conclusions

Cancer patients with TTS are characterized by different clinical features, epidemiological characteristics, worse prognosis and higher long-term mortality when compared to patients with TTS without history of malignancy. A distinct inflammatory pattern can be found in this subset of TTS patients.
290 The impact of ‘the medication non-adherence’ in patients with cardiovascular disease: causes, outcomes, and interventions. Review of the literature
Authors: Giordano Vincenza , Cardillo Luca
Published: December 2021

Aims

The adherence of the pharmacological prescriptions, for patients affected by cardiovascular chronic diseases is one of the most difficult challenges and it’s very important for the clinical efficiency of the therapy. A weak medication adherence or the non-adherence is associated with an increase in health care interventions, an increase in mortality and morbidity, and they can negatively affect the citizens and the sustainability health care system. It’s very important to pay attention to this adhesion and it is a discussed topic in the cardiovascular field. Identify the causes of medication weak adherence and/or medication non-adherence used in cardiovascular diseases and determine the resulting unfavorable clinical outcomes and possible solutions to reduce this phenomenon.

Methods and results

A systematic search was carried out using databases such as PUBMED and CINAHL. The inclusion criteria established, so that an article could be used, was the relevance to the topic. From the studies analyzed for the preparation of the review, it is clear that the main causes of weak adherence and/or non-adherence to drug are the long duration of the therapies, the patient’s age, and the complexity of the therapy. All this leads to unfavorable outcomes for the patient, thus determining an increase in the number of outpatient visits with the risk of hospitalization or re-hospitalization, up to an increase in mortality and/or morbidity.

Conclusions

The medication weak adherence or the medication non-adherence is a crucial element in the cardiovascular field that requires intervention to reduce adverse outcomes. The methods to reduce this phenomenon include health education, the interaction between patient and professionals, medical deprescribing, and the use of electronic control devices which, in recent years, have proved to be perfect allies in adherence.
38 Transcatheter tricuspid valve edge-to-edge repair in patient with severe tricuspid regurgitation and previous mitraclip treatment: when four orifices are better than two
Authors: Cacia Michele Antonio , Mongiardo Annalisa , Spaccarotella Carmen Anna Maria , Boccuto Fabiola , Serratore Serena , Aquila Iolanda , Mascaro Giuseppina , Indolfi Ciro
Published: December 2021

An 82 years old woman was admitted to our Division for worsening dyspnoea. Her past medical history showed: arterial hypertension, chronic atrial fibrillation on oral anticoagulation, a non-critical single-vessel coronary artery disease, previous mitral transcatheter edge-to-edge repair through 2 Mitraclip NTR. After an initial improvement in clinical symptoms following Mitraclip implantation, the patient was admitted several times for acute decompensated heart failure. Haematological exams at admission were normal, exception of NTproBNP (1909 pg/mL). The ECG documented atrial fibrillation with normal ventricular rate. Transthoracic echocardiography demonstrated mid-range heart failure (EF 45–50%) with D-shape morphology of the left ventricle. Colour-doppler analysis shows presence of Mitraclip devices in place with mild residual insufficiency, dilation of the right side, torrential tricuspid regurgitation (tTR) with estimated pulmonary arterial pressure of 45 mmHg. Preprocedural transesophageal echocardiography confirmed these findings showing dilation of the tricuspid annulus with two large regurgitating jets.

After positioning Amplatzer Superstiff guide in superior vena cava through guide catheter TSGC0202, a Triclip XT was placed in commissural region between anterior and septal leaflets. A two-grade reduction in tricuspid regurgitation (TR) grade from torrential (5+) to moderate (3+) was achieved without significant transvalvular gradient. The patient was successful discharged after 2 days, asymptomatic and in good clinical conditions. A great reduction in NTproBNP values at discharge was observed (1612 pg/mL). We report a case of successful tricuspid transcatheter repair in patient with chronic decompensated heart failure and previous Mitraclip treatment. The clinical impact of TR reduction is probably due to a positive right ventricular (RV) remodelling, with a reduction in RV size. RV dysfunction and its implications (liver, renal, and haemostatic consequences) are definitely a matter of concern for fragile patients with TR. In fact, many patients with severe TR have a reduced RV function. The reduction in volume and pressure overload of the right heart side, the progressive anatomic and functional reverse of the RV disfunction, may lead to a significant clinical benefit and to a lower hospitalizations rates also through to an important improvement of the left ventricular function as a consequence of the reduction in pressure overload.
657 Right ventricle systolic function and RV-PA coupling in patients with severe aortic stenosis and the early impact of TAVI
Authors: Lillo Rosa , Graziani Francesca , Ingrasciotta Gessica , Przbybylek Bianca , Iannaccone Giulia , Locorotondo Gabriella , Pedicino Daniela , Aurigemma Cristina , Romagnoli Enrico , Trani Carlo , Lanza Gaetano Antonio , Lombardo Antonella , Burzotta Francesco , Massetti Massimo
Published: December 2021

Aims

Few data are available on the prevalence of right ventricle (RV) systolic dysfunction, assessed including RV strain, and RV to pulmonary artery (PA) coupling in patients with aortic stenosis (AS) submitted to TAVI and the early effect of the procedure.

Methods

We performed standard and speckle tracking echocardiography in 80 patients with severe AS the day before TAVI and within 48 h after TAVI. In all patients we measured TAPSE/PASP (cut-off for RV-PA uncoupling 0.31) and in 60/80 we were able to analyse RV global longitudinal strain (RV-GLS) and RV free wall strain (RV-FWS).

Results

RV-FAC and TAPSE were impaired in 8.3% while RV-GLS and RV-FWS in 45% and 33% before TAVI. TAPSE/PASP<0.31 was documented in 7/80 patients (8.7%) before TAVI. These subjects differed from patients with TAPSE/PASP>0.31 for: enlarged left ventricular (LV) end-diastolic and end-systolic volumes (P<0.001), worst LVEF (P<0.001) and RVFAC (P<0.001), worst RV-GLS and RW-FWS (P=0.01 and P=0.03) and bigger right atrium (RA) area (P<0.001). After TAVI, RV systolic function did not improve while PASP significantly decreased (P=0.005) driving the improvement of TAPSE/PASP (P=0.01). Patients with TAPSE/PASP improvement (51%) differed from the others for worst pre-TAVI diastolic function (E/e’ P=0.045), RV-FAC (P=0.042), RV-GLS (P=0.049) and RA area (P=0.02).

Conclusions

RV-GLS unveils RV systolic dysfunction in as much as 45% of patients with AS vs. only 8.3% revealed by conventional echocardiography. RV systolic function does not significantly improve early after TAVI while RV-PA coupling does. Patients with lower TAPSE/PASP at baseline have worst LV and RV systolic function as well as larger RA. Patients who improve TAPSE/PASP after TAVI are those with worst diastolic function, RV systolic function and larger RA at baseline.
365 Combining mechanisms of prosthetic valve dysfunction
Authors: Menè Roberto , Tomaselli Michele , Gavazzoni Mara , Maisano Francesco , Parati Gianfranco , Giannattasio Cristina , Badano Luigi
Published: December 2021

A 32-year-old female was referred to our outpatient clinic for exertional dyspnoea that had worsened in the preceding months. She had a history of mitral and aortic valve replacement with bileaflet mechanical prosthesis (St. Jude Master n. 25 and Medtronic Open Pivot n. 16, respectively) for rheumatic heart disease. A recent echocardiography showed borderline-high trans-aortic gradients (mean 26 mmHg, peak 42 mmHg). Transthoracic echocardiography revealed abnormal aortic transprosthetic flow (peak velocity 442 cm/s, mean gradient 48 mmHg). Continuous Wave Doppler signal was rounded with a long acceleration time (108 ms). Effective orifice area (EOA) was 0.8 cmq (index EOA 0.48 cmq/mq) and Doppler Velocity Index 0.28. Further investigations revealed no signs of infections but suboptimal anticoagulation (INR 2.5). Transesophageal 3D echocardiography was suggestive for hypomobility of the prosthetic leaflets and the presence of an isoechoic mass encircling the ventricular side of the aortic prosthesis compatible with pannus overgrowth. Cardiac CT confirmed the presence of a symmetrical reduction in the systolic opening of both leaflets. The patient underwent a redo of aortic valve replacement that confirmed the presence of an asymmetric subprosthetic pannus overgrowing on the previously implanted surgical pledgets. After pannus debritment a St. Jude Regent n. 21 was implanted. The patient experienced complete symptomatic resolution. We presented the case of a prosthetic aortic valve dysfunction due to a combination of patient-prosthesis mismatch and pannus overgrowth. In our patient, as assessed in the old echocardiographic examinations, the presence of mildly elevated transprosthetic gradients was suggestive for prosthesis undersizing related to body surface area. In this scenario, subvalvular pannus formation caused significant changes in prosthetic valve transvalvular flow dynamic leading to prosthesis dysfunction. This case emphasises the crucial role of echocardiographic follow up in detection of causes of prosthetic heart valve dysfunction and how optimal valve sizing is paramount in aortic valve replacement.
699 Incidence of COPD in primary and secondary outcomes in patients undergoing a TAVI
Authors: Alkhoury Elie , Prandi Francesca Romana , Pensabene Giulia , Di Luozzo Marco , Marchei Massimo , Macrini Massimiliano , Romeo Francesco , Muscoli Saverio
Published: December 2021

Aims

The association between severe chronic obstructive pulmonary disease (COPD) and in-hospital mortality (IHM) as well as incidence of post-procedural intubation and length of in-hospital stay (LOHS) in patients with severe aortic stenosis (AS) undergoing transfemoral (TF) transcatheter aortic valve implantation (TAVI) is still unclear. We evaluated the impact of severe COPD on IHM, post-procedural tracheal intubation and LOHS in patients with severe AS undergoing TF TAVI.

Methods

We retrospectively analysed a total of 550 consecutive patients who underwent transfemoral TAVI in our centre between 2011 and 2021. We divided the patients in Group 1 (affected by severe COPD) and Group 2 (without COPD). We further divided the patients affected by COPD into Subgroup A (on COPD medical treatment) and Subgroup B (without COPD medical treatment).

Results

A total of 550 patients who underwent TF TAVI were included in this analysis. 38.55% (n=212) had a diagnosis of COPD (Group 1) and 61.45% (n=338) were not affected by COPD (Group 2). In Group 1, 29.38% (n=62) of patients were receiving medical treatment for COPD (Subgroup A), while 70.6% (n=149) were not on COPD medications (Subgroup B). The mean age was 81.83±6.67 in Group 1 vs. 81.33±7.21 in Group 2 (P=0.45), and 82.12±7.6 in Subgroup A vs. 82.14±6.82 in Subgroup B (P=0.98). The gender distribution showed 127 (45%) men in Group 1 vs. 96 (50%) men in Group 2 (P=0. 33), and 21 (42%) men in Subgroup 1 vs. 75 (53%) men in Subgroup B (P=0.28). The mean EUROSCOREII was 8.26±7.03 in Group 1 vs. 6.81± 7.57 in Group 2, P= 0.11, and 7.24±5.49 in Subgroup A vs. 9.30±7.5 in Subgroup B, P=0.52. There was no difference observed for in-hospital mortality between Group 1 and Group 2 (0.04% vs. 0.05%; P=0.6) and between Subgroup A and Subgroup B (0.04% vs. 0.04%; P=0.7). Similarly, the incidence of post-procedural intubation was comparable between Group 1 and Group 2 (0.06% vs. 0.03%; P=0.18), and between Subgroup A and Subgroup B (0.08% vs. 0.05%; P=0.78). Finally, also the mean length of in-hospital stay was similar between Group 1 and Group 2 (10±4.46 days vs. 9.68± 5.02 days; P=0.47), and between Subgroup A and Subgroup B (10.36±4.24 days vs. 9.87±4.54 days; P=0.5).

Conclusions

In patients with severe aortic stenosis treated with transfemoral TAVI, the presence of severe COPD does not affect in-hospital mortality, incidence of post-procedural intubation and length of in-hospital stay. COPD medications do not impact any of the outcomes evaluated. Therefore, TF TAVI is a safe procedure also for patients affected by severe chronic obstructive pulmonary disease that are not on COPD medications.
227 Myocardial work evaluation in severe aortic stenosis undergoing transcatheter aortic valve implantation
Authors: Sperlongano Simona , Renon Francesca , Del Giudice Carmen , Iannuzzi Angela , Bocchetti Marco , D'aquino Marco Malvezzi Caracciolo , Liccardo Biagio , Scognamiglio Gabriella , Salerno Gemma , Ciccarelli Giovanni , Bianchi Renato , Tartaglione Donato , Bigazzi Maurizio Cappelli , Golino Paolo
Published: December 2021

Aims

Myocardial work (MW) is a novel echocardiographic technique which assesses left ventricular (LV) performance through LV pressure-strain loops. MW corrects speckle tracking echocardiography (STE)-derived parameters for afterload using non-invasive systolic blood pressure (SBP) as a surrogate for LV systolic pressure. In patients with severe aortic stenosis (AS), the corrected MW (cMW) has been proposed, consisting in adding the mean aortic gradient in SBP. This method revealed to be feasible and reliable, demonstrating good correlation with invasively measured LV systolic pressure.

To evaluate myocardial performance of patients with severe AS, before and after transcatheter aortic valve implantation (TAVI), by MW indices.

Methods

patients with severe AS undergoing TAVI were included. Transthoracic, standard echocardiography and STE were performed the day before the procedure and within 2 days after. MW was calculated by combining STE-derived indices with non-invasively estimated LV systolic pressure.

Results

30 patients (79±5 years old, 56% females) with severe AS (mean gradient 47±14 mmHg, aortic valve area 0.6±0.1 cm2), and eligible for TAVI were enrolled. Baseline global longitudinal strain was impaired (GLS −15±4%), in presence of normal LV ejection fraction (LVEF 57±10%). Corrected global work index and global constructive work were preserved at baseline and markedly decreased after TAVI (cGWI 2322±791 vs. 1710±505 mmHg%, P=0.001; cGCW 2774±803 vs. 2083±536 mmHg%, P=0.0007). Corrected global wasted work and global work efficiency were respectively higher and lower than reference values existing in literature, and no significant changes were observed after TAVI (cGWW 276±174 vs. 277±165 mmHg%, P=0.974; cGWE 89±5 vs. 87±5%, P=0.177). A significant inverse correlation was found between baseline cGWI and left atrial volume index (r = −0.5, P=0.03).

Conclusions

Patients with severe aortic stenosis and preserved LVEF show a good LV performance before and after TAVI, with a significant decrease in MW indices after TAVI, because of the reduced afterload due to AS treatment. The negative correlation between left atrial volume and cGWI may reflect the extent of myocardial damage in AS. However, further studies with larger sample size and appropriate follow-up are needed to evaluate the role of MW in prognosis and risk stratification of this subset of patients.
595 Impact of age on outcomes in a large multicentre low-to-intermediate risk TAVI population: in and out the age cut-off from ESC 2021 valvular heart disease guidelines
Authors: Sticchi Alessandro , Gallo Francesco , Benenati Stefano , Won-keun Kim , Khokhar Arif A , Zeus Tobias , Toggweiler Stefan , De Marco Federico , Reimers Bernhard , Nombela-franco Luis , Barbanti Marco , Brugaletta Salvatore , Piva Tommaso , Rodes-cabau Josep , Porto Italo , Colombo Antonio , Giannini Francesco
Published: December 2021

Aims

The ESC 2021 valvular heart disease [VHD] guidelines introduced an important and debated age cut-off (75 years) to lead the choice between surgical and transcatheter aortic valve implantation (TAVI) in non-high-risk patients. The aim of this study was to evaluate what impact an age cut-off has on clinical outcomes following TAVI in low-to-Intermediate Risk patients from a real word registry.

Methods

We performed the investigation in a large, contemporary, real-world, multicentre, international, retrospective registry of 3862 consecutive patients, comparing the rates of patient risk factors, procedural characteristics, complications, and outcomes in the populations with < or ≥ 75 years old.

Results

In our real-world cohort of 2977 patients with mean STS score of 3.6% (5.0–2.5), we found 301 (10.1%) patients with age <75 years and 2676 (89.9%) with ≥75 years. In the younger group compared with the older, we have a higher prevalence of male (44% vs. 35%, P=0.003), higher BMI (mean of 28.5 kg/m² vs. 26.7 kg/m², P = <0.001), diabetes (32% vs. 26%, P=0.027), insulin-dependent diabetes (12% vs. 7%, P=0.001), smoking (18% vs. 7%, P<0.001), COPD (26% vs. 16%, P<0.001). Moreover, younger patients presented less previous PM/ICD (6% vs. 11%, P=0.023), less atrial fibrillation (24% vs. 33%, P=0.033), less renal impairment (30% vs. 66%, P<0.001) and a lower mean STS score (2.6% vs. 3.7%, P<0.001). There was no difference in annular sizing, valvular and LVOT calcifications between the two groups. Older patients had a higher prevalence of porcelain aorta (2% for age<75 vs. 9%, P=0.001). Between the two groups no significant differences in procedural characteristics were observed, including rates of pre-dilatation (P=0.369), post-dilatation (P=0.159) and contrast volume (P=0.259). Procedural complications, in-hospital outcomes and 2-year Kaplan-Meier (KM) survival was equivalent between both groups (P=0.930). Finally, we assessed the best age cut-off related to 1-year mortality in our population, resulting in 86 years. Still, also in this scenario, the KM survival analysis did not show significant differences (P=0.120).

Conclusions

In our large real-world contemporary low-to-intermediate risk TAVI population, an age cut-off of 75 years was not associated with any difference in clinical outcomes and survival at 2-years follow-up. This data reinforces the concept that age alone is not a sufficient variable to be considered when choosing between TAVI or SAVR. The recent ESC 2021 VHD guidelines cut-off is justified only by the lack of evidence and valve durability strategy but not of a proper advantage age-related.
597 Comparison between low versus intermediate-high risk patients in a contemporary real-world multicentre TAVI registry using self-expanding supra-annular valves: a propensity score matched analysis
Authors: Sticchi Alessandro , Gallo Francesco , Benenati Stefano , Won-keun Kim , Khokhar Arif A , Zeus Tobias , Toggweiler Stefan , De Marco Federico , Reimers Bernhard , Nombela-franco Luis , Barbanti Marco , Brugaletta Salvatore , Piva Tommaso , Rodes-cabau Joseph , Porto Italo , Colombo Antonio , Giannini Francesco
Published: December 2021

Aims

Recent ESC VHD guidelines from 2021 recommend TAVI for intermediate-risk and in certain cases low-risk populations. There is relatively little data regarding the impact of transcatheter heart valve design in these populations. The aim of this study was to investigate the clinical outcomes of low-risk versus intermediate-high risk patients following TAVI in a large real-world contemporary registry.

Methods

In a large TAVI registry using self-expanding supra-annular bioprosthesis, we performed a comparison between low vs. intermediate-high risk population. Primary outcome was 1-year mortality and secondary outcomes, defined according to Valve Academic Research Consortium 2 criteria, included major and minor vascular complications, annular rupture, myocardial infarction, cardiac tamponade, new permanent pacemaker, stroke, and major and minor bleeding. Finally, we assessed the same investigation applying a propensity score matched (PSM) analysis.

Results

In the unmatched comparison, the low-risk (LR) group included 1698 patients compared to the 1690 patients of the Intermediate-to-high risk group (IHR). The IHR population showed a mean age of 84 years old vs. 81 of the LR (P<0.001), a higher prevalence of male sex (41% vs. 30%, P<0.001) and increased prevalence of co-morbidities as evidenced by the higher mean STS score 5.80% vs. 2.63% (P<0.001). About the echocardiographic characteristics, the LR presented a higher mean gradient (45.9±15 mmHg vs. 43.7±16.8 mmHg, P<0.001) but similar area compared to the IHR group (0.7 [0.8–0.6] for LR and 0.7 (0.8–0.55) for IHR, P=0.096). In the first unmatched comparison, we found a higher rate of major vascular complications (5.4% vs. 7.3%, P=0.026), new permanent pacemaker (10.5% vs. 13.7%, P=0.006) and major bleeding (2.9% vs. 5.0%, P=0.002) for the IHR group. After the PSM, we obtained 1015 matched patients observing similar outcomes except for minor vascular complications (7.4% vs. 11%, P=0.014) for the IHR group. At a median follow-up of 368 days, the mortality rate was 12.2% (104/1559) vs. 6.8% (104/1520) for the un-matched populations (P<0.001), and 10.4% (98/940) vs. 7.9% (71/898) for the matched patients (P=0.100), respectively for the IHR and the LR group.

Conclusions

In this large, contemporary real-world registry of TAVI patients, there was no difference in mortality observed between LR and IHR populations at a 1-year follow-up. This data suggests that additional factors beyond surgical risk scores should be considered during heart team evaluation of patients with severe aortic stenosis towards a single-patient tailored approach.
681 Ventricular fibrosis affects diastolic function and atrial remodelling long-term after aortic valve replacement for aortic valve stenosis
Authors: Tadiello Enrico , Trento Laura , Setti Martina , De Conti Giorgia , Onorati Francesco , Faggian Giuseppe , Zamboni Mauro , Rossi Andrea , Benfari Giovanni , Ribichini Flavio
Published: December 2021

Aims

Aortic stenosis (AS) is characterized both by progressive valve narrowing and left ventricular remodelling response. Myocardial fibrosis has significant functional consequences and is the key pathological process driving left ventricular decompensation. Furthermore, studies suggest that myocardial fibrosis is irreversible, despite surgical aortic valve replacement (SAVR). The study aims to define the association between myocardial fibrosis and long-term diastolic and atrial function after SAVR, which are both markers of poor clinical outcomes.

Methods

We evaluated patients with isolated AS and no-coronary artery disease referred for SAVR in 2015. All of them received a biological valve and a left ventricular biopsy was performed at the time of surgery. Clinical and echocardiographic evaluation was performed before surgery and after about 6 years, including fully automated 2D speckle tracking analysis software (TomTec). Atrial function was evaluated with PALS, PACS, and LAVi/septal a’ TDI.

Results

Nineteen patients completed the follow-up and formed the study cohort, age 72 ± 6 years, 42% female, ejection fraction 63 ± 6.4%, mean fibrosis 26.4 ± 12.7%. Significant myocardial fibrosis (> 33%) was found in 13/19 patients (68%). Although similar at baseline, after 5.6±0.5 years, PACS was significantly higher in patients with low myocardial fibrosis (13.7±4.2 vs. 8.0±3.8, P=0.01), the same trends were observed for PALS (24.1±7.9 vs. 17.0±6.6, P=0.07) and LAVi/septal a’TDI (5.4±1.3 vs. 7.4±2.8, P=0.06). The diastolic profile at long term follow-up was also significantly worsened in patients with LV fibrosis: E/A 0.9±0.3 vs. 1.3±0.4 P= 0.03 and E/e’ 10.6±3.3 vs. 16.6±4.5 P=0.01).

Conclusions

Myocardial fibrosis at the time of SAVR strongly influences long-term diastolic Doppler profile and atrial function with potentially harmful consequences on clinical status and ventricular performance.